Redburn Atlantic initiated coverage of Alnylam with a Buy rating and $353 price target Therapeutic options for patients with transthyretin ...

Cantor Fitzgerald said that while the firm “congratulates” Alnylam Pharmaceuticals (ALNY) on last week’s Amvuttra approval, with the stock ...

The U.S. Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of ...

AMVUTTRA is an RNAi therapeutic that works ... M.D., Chief Medical Officer of Alnylam. “Data showing beneficial effects on cardiac systolic and diastolic function are novel and indicate the ...

Four years after getting the first drug approved by the FDA to treat rare disease hereditary ATTR amyloidosis, Alnylam has got the go-ahead for a second – Amvuttra – which has a simpler ...

MONDAY, March 24, 2025 (HealthDay News) -- The U.S. Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of people. The drug, called ...

Alnylam Pharmaceuticals (NASDAQ ... polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults ...

said in a news release by Alnylam, the maker of Amvuttra. "The availability of this groundbreaking treatment option is a significant moment for patients living with ATTR amyloidosis. It ...

Vutrisiran is already approved as Amvuttra to treat rare disease hereditary ATTR amyloidosis, so approval in Stargardt disease would prompt the pricing negotiation mechanism. Alnylam's earlier ...

Last week, the agency signed off on Alnylam’s Amvuttra to treat transthyretin amyloid cardiomyopathy (ATTR-CM) patients. Sanofi originally partnered on the development of both Amvuttra and Qfitlia.

Alnylam Pharmaceuticals ... the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI ...